JB Chemicals & Pharmaceuticals Ltd. (JBCHEPHARM) AI Stock Analysis

• Market Cap: ₹264.63B
• Dividend Yield: 0.91%
• Average Volume (3M): 2.67K
• Price to Earnings (P/E): 38.5
• Beta (1Y): 0.54
• Revenue Growth: 11.56%
• EPS Growth: 16.30%
• Country: IN
• Employees: 5,311
• Sector: Healthcare
• Sector Strength: 45
• Industry: Drug Manufacturers - Specialty & Generic
• EPS (TTM): 13.70
• Shares Outstanding: 156,596,240
• 10 Day Avg. Volume: 4,569
• 30 Day Avg. Volume: 2,671
• PEG Ratio: 1.96
• Price to Book (P/B): 7.17
• Price to Sales (P/S): 6.28
• P/FCF Ratio: 30.57
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: Hold
• Number of Analyst Covering: 0

• Rating: 73 Outperform
• Price Target: ₹1,892.00 ▲(11.49% Upside)

JB Chemicals & Pharmaceuticals Ltd. scores well due to its strong financial performance, characterized by robust revenue growth and financial stability. However, the high valuation and neutral technical indicators slightly temper the overall score. The absence of recent earnings call data and corporate events means these factors do not influence the score.

JB Chemicals & Pharmaceuticals Ltd. Business Overview & Revenue Model

Company Description

JB Chemicals & Pharmaceuticals Ltd. (JBCHEPHARM) is a leading Indian pharmaceutical company engaged in the development, manufacturing, and marketing of a wide range of pharmaceutical products. The company operates primarily in the sectors of formulations, active pharmaceutical ingredients (APIs), and generics. JBCHEPHARM specializes in producing high-quality medicines across various therapeutic segments, including cardiology, gastroenterology, and anti-infectives, catering to both domestic and international markets.

How the Company Makes Money

JBCHEPHARM generates revenue through multiple streams, primarily from the sale of its pharmaceutical formulations and active pharmaceutical ingredients. The company markets its products through a well-established distribution network, which includes both wholesalers and retail pharmacies. Additionally, JBCHEPHARM earns revenue from exports, significantly contributing to its earnings as it caters to various international markets. The company's strategic partnerships with healthcare providers and distributors further enhance its market presence and revenue potential. Moreover, JBCHEPHARM invests in research and development to innovate and expand its product portfolio, thereby driving growth and increasing its competitive advantage in the pharmaceutical industry.

JB Chemicals & Pharmaceuticals Ltd. Financial Statement Overview

Summary

JB Chemicals & Pharmaceuticals Ltd. demonstrates strong financial performance with robust revenue growth, efficient cost management, and solid profitability metrics. The balance sheet is stable with low leverage, and cash flows are strong, though capital expenditure management requires attention.

Income Statement

JB Chemicals & Pharmaceuticals Ltd. has demonstrated strong revenue growth with a notable increase in total revenue from INR 24.2 billion to INR 39.2 billion in the latest annual period. The gross profit margin is impressive, reflecting efficient cost management, and the net profit margin has improved, indicating enhanced profitability. The EBIT and EBITDA margins also show a positive trajectory, supporting the company's stable financial performance.

Balance Sheet

The company's balance sheet is solid with a low debt-to-equity ratio, showcasing financial stability and low leverage risk. The return on equity is commendable, reflecting effective utilization of shareholder funds. The equity ratio is strong, indicating a healthy proportion of assets financed by equity. Overall, the balance sheet reflects financial robustness with moderate risk.

Cash Flow

JB Chemicals & Pharmaceuticals Ltd. exhibits a strong operating cash flow relative to net income, highlighting efficient cash generation from operations. The free cash flow has grown significantly, which bodes well for future investments and shareholder returns. However, fluctuations in capital expenditures could pose potential risks to sustaining cash flow growth.

Breakdown	TTM	Dec 2025	Dec 2024	Dec 2023	Dec 2022	Dec 2021
Income Statement
Total Revenue	40.08B	39.18B	34.84B	31.17B	24.24B	20.06B
Gross Profit	22.34B	26.01B	13.46B	11.14B	15.61B	12.88B
EBITDA	10.81B	10.32B	9.33B	7.04B	5.82B	6.72B
Net Income	6.85B	6.60B	5.53B	4.10B	3.85B	4.48B
Balance Sheet
Total Assets	0.00	42.74B	39.94B	35.54B	26.07B	22.38B
Cash, Cash Equivalents and Short-Term Investments	4.50B	4.50B	4.60B	2.69B	566.50M	6.94B
Total Debt	0.00	278.90M	3.78B	5.72B	545.59M	449.88M
Total Liabilities	-34.33B	8.40B	10.71B	10.74B	4.69B	4.25B
Stockholders Equity	34.33B	34.33B	29.23B	24.80B	21.34B	18.10B
Cash Flow
Free Cash Flow	0.00	8.05B	5.39B	-1.39B	-5.37B	2.67B
Operating Cash Flow	0.00	9.02B	8.01B	6.26B	1.70B	3.15B
Investing Cash Flow	0.00	-2.96B	-4.08B	-9.62B	23.20M	-2.31B
Financing Cash Flow	0.00	-5.80B	-3.41B	3.57B	-1.38B	-874.23M

JB Chemicals & Pharmaceuticals Ltd. Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 1697.05
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IN:JBCHEPHARM, the sentiment is Positive. The current price of 1697.05 is above the 20-day moving average (MA) of 1681.35, below the 50-day MA of 1699.83, and above the 200-day MA of 1668.87, indicating a bullish trend. The MACD of 1.79 indicates Negative momentum. The RSI at 55.81 is Neutral, neither overbought nor oversold. The STOCH value of 61.22 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for IN:JBCHEPHARM.

JB Chemicals & Pharmaceuticals Ltd. Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
JBCHEPHARM	―	₹264.63B	38.46	―	0.91%	11.56%	16.30%
AJANTPHARM	―	₹304.66B	32.75	―	2.26%	10.92%	9.76%
PFIZER	―	₹243.86B	30.33	―	0.67%	4.35%	32.89%
GLAND	―	₹318.91B	41.40	―	0.94%	-2.34%	6.64%
Sector *	―	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
GLENMARK	―	₹522.88B	69.69	―	0.13%	10.99%	―

JB Chemicals & Pharmaceuticals Ltd. Corporate Events

JB Chemicals Announces Director Cessation

JB Chemicals & Pharmaceuticals Ltd. announced the cessation of Ms. Padmini Khare Kaicker as a Non-Executive Independent Director, effective August 30, 2025, following the completion of her five-year term. This change reflects the company’s adherence to regulatory requirements and governance practices, potentially impacting its board dynamics and strategic direction.

JB Chemicals & Pharmaceuticals Releases Q1 FY ’26 Earnings Call Transcript

JB Chemicals & Pharmaceuticals Ltd. has released the transcript of its Q1 FY ’26 earnings conference call, held on July 31, 2025, for investors and analysts. The call, which discussed the company’s financial results and strategic developments for the first quarter ending June 30, 2025, is available on the company’s website. The release of this transcript is part of the company’s ongoing efforts to maintain transparency and keep stakeholders informed about its financial performance and strategic direction.